This follows on from the original BIOMEDE phase II trial (NCT02233049), which included DMG and evaluated everolimus, dasatinib, or erlotinib combined with radiotherapy, assigned on the evaluation of PTEN-loss or EGFR-overexpression from (brainstem) tumor biopsy, introduced as a paradigm shift via this trial (123). This evidence concerns the gene EGFR and neoplasm.